Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Despite the obvious benefits of adding immune checkpoint inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC), real-world data remain scarce. Methods: This retrospective study included 89 patients with ES-SCLC treated with platinum-etoposide chemotherapy alone (chemo-only group; n = 48) or in combination with atezolizumab (atezolizumab group; n = 41) and compared the survival outcomes between these two groups. Results: Overall survival (OS) was significantly longer in the atezolizumab group than in the chemo-only group (15.2 months vs. 8.5 months; p = 0.047), whereas the median progression-free survival was almost the same (5.1 months vs. 5.0 months) in both groups (p = 0.754). Subsequent multivariate analysis revealed that thoracic radiation (hazard ratio [HR], 0.223; 95% confidence interval [CI], 0.092–0.537; p = 0.001) and atezolizumab administration (HR, 0.350; 95% CI, 0.184–0.668; p = 0.001) were favorable prognostic factors for OS. In the thoracic radiation subgroup, patients who received atezolizumab demonstrated favorable survival outcomes and no grade 3–4 adverse events (AEs). Conclusions: The addition of atezolizumab to platinum-etoposide resulted in favorable outcomes in this real-world study. Thoracic radiation was associated with improved OS and acceptable AE risk in combination with immunotherapy in patients with ES-SCLC.
Abstract
Background/Aims: Despite the obvious benefits of adding immune checkpoint inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC), real-world data remain scarce. Methods: This retrospective study included 89 patients with ES-SCLC treated with platinum-etoposide chemotherapy alone (chemo-only group; n = 48) or in combination with atezolizumab (atezolizumab group; n = 41) and compared the survival outcomes between these two groups. Results: Overall survival (OS) was significantly longer in the atezolizumab group than in the chemo-only group (15.2 months vs. 8.5 months; p = 0.047), whereas the median progression-free survival was almost the same (5.1 months vs. 5.0 months) in both groups (p = 0.754). Subsequent multivariate analysis revealed that thoracic radiation (hazard ratio [HR], 0.223; 95% confidence interval [CI], 0.092–0.537; p = 0.001) and atezolizumab administration (HR, 0.350; 95% CI, 0.184–0.668; p = 0.001) were favorable prognostic factors for OS. In the thoracic radiation subgroup, patients who received atezolizumab demonstrated favorable survival outcomes and no grade 3–4 adverse events (AEs). Conclusions: The addition of atezolizumab to platinum-etoposide resulted in favorable outcomes in this real-world study. Thoracic radiation was associated with improved OS and acceptable AE risk in combination with immunotherapy in patients with ES-SCLC.
참고문헌 (17)
- "Cancer Facts & Figures 2022" (2022)[URL]
- Gazdar AF, "Small-cell lung cancer : what we know, what we need to know and the path forward", Nat Rev Cancer, 17, pp.725~737 (2017)
- Sabari JK, "Unravelling the biology of SCLC : implications for therapy", Nat Rev Clin Oncol, 14, pp.549~561 (2017)
- Rudin CM, "Molecular subtypes of small cell lung cancer : a synthesis of human and mouse model data", Nat Rev Cancer, 19, pp.289~297 (2019)
- Horn L, "First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer", N Engl J Med, 379, pp.2220~2229 (2018)
- Paz-Ares L, "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN) : a randomised, controlled, open-label, phase 3 trial", Lancet, 394, pp.1929~1939 (2019)
- Mathieu L, "FDA approval summary : atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer", Oncologist, 26, pp.433~438 (2021)
- Elegbede AA, "A real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC in Canada", JTO Clin Res Rep, 2, pp.100249~ (2021)
- Lee S, "Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage smallcell lung cancer : a single-center experience", Cancer Immunol Immunother, 71, pp.1093~1101 (2022)
- "Smoking status recodes" (2015)[URL]
- Slotman BJ, "Use of thoracic radiotherapy for extensive stage small-cell lung cancer : a phase 3 randomised controlled trial", Lancet, 385, pp.36~42 (2015)
- Welsh JW, "Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer", J Thorac Oncol, 15, pp.266~273 (2020)
- Gore EM, "Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer(ED SCLC) : NRG oncology RTOG 0937", J Thorac Oncol, 12, pp.1561~1570 (2017)
- Expert Panel Thoracic Malignancies, "American Radium Society appropriate use criteria on radiation therapy for extensive-stage SCLC", J Thorac Oncol, 16, pp.54~65 (2021)
- Borcoman E, "Novel patterns of response under immunotherapy", Ann Oncol, 30, pp.385~396 (2019)
- Champiat S, "Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1", PD-L1, 2017, pp.23, 1920~1928
- Kim J, "Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment", Thorac Cancer, 13, pp.2170~2179 (2022)